Skip to main content
Premium Trial:

Request an Annual Quote

Sirna Revenues Down for Q4 Amid Narrowed Net Loss

NEW YORK, Feb. 5 (GenomeWeb News) - Sirna Therapeutics, of Boulder, Colo., reported $420,000 in revenues for the quarter, down slightly from the prior year period, amid narrowed net losses.

 

The company, which changed its name from Ribozyme last April to reflect its new focus on siRNA-based therapeutics, reported net losses of $6.1 million for the quarter ended Dec. 31, down from $10,342.

 

R&D expenses came to $5.1 million, down from $8.4 million in the fourth quarter of last year.

As of Dec. 31, 2003, the company had $36.6 million in cash, cash equivalents and securities available for sale.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.